Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Moxidectin is indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older.
• This summary is based on the review of two systematic review(s)/meta-analysis(es). ^[1-2]
• Moxidectin has been clinically evaluated for its efficacy in treating Strongyloides stercoralis and Trichuris trichiura infections, with the review assessing its effectiveness both as a monotherapy and in combination with other antiparasitic medications.
• Moxidectin is globally approved for treating endo- and ecto-parasites across 13 mammalian species, as highlighted by the review of 35 studies, though the methodological quality varied.
• The studies provided do not specify any comparative effectiveness with other drugs or significant differences in efficacy among various population types or subgroups.
• There is no specific safety information available regarding moxidectin in treating Strongyloides stercoralis and Trichuris trichiura infections based on the provided studies.
• Mild adverse effects were reported in a small percentage of individuals treated with moxidectin for general parasite treatment in mammalian species; these symptoms resolved without additional therapies.
• There is no population types or subgroups information available in the reviewed studies.